Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma

Luwei Tao, Ruoyu Miao, Tarek Mekhail, Jingxin Sun, Lingbin Meng, Cheng Fang, Jian Guan, Akriti Jain, Yuan Du, Amanda Allen, Brenda L Rzeszutko, Mark A Socinski, Chung-Che Chang
July, 2020
Cite Source Document DOI
Image credit: CLC

Abstract

The prognostic value of different KRAS (Kirsten rat sarcoma viral oncogene) mutation subtypes and their association with programmed death ligand 1 (PD-L1) expression in lung adenocarcinoma (LADC) remain unclear. We examined the association of KRAS mutation subtypes with clinical outcomes and PD-L1 expression status.

Type
Journal article
Publication
Clinical Lung Cancer
Lung Caner Gene Survival Driver mutation Immunotherapy Molecular profiling Precision medicine Prognosis
Yuan Du
Yuan Du
Senior Data Scientist

My interests include applied Statistics, Machine Learning, Deep Learning and Healthcare.